CVKD | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 24%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

5.33%

1 Month

-3.49%

3 Months

-28.18%

6 Months

-60.88%

1 Year

-67.47%

2 Year

1,190.85%

Key data

Stock price

$5.53

P/E Ratio

0.00

DAY RANGE

$5.32 - $5.96

EPS

-$9.01

52 WEEK RANGE

$4.21 - $17.50

52 WEEK CHANGE

-$67.08

MARKET CAP

28.269 M

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.42

PUBLIC FLOAT

AVERAGE 10 VOLUME

$64,898

AVERAGE 30 VOLUME

$49,117

Company detail

CEO: Quang Pham
Region: US
Website: www.cadrenal.com
Employees: 0
IPO year: 2023

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Our principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida.

CVKD - Cadrenal Therapeutics Inc